Literature DB >> 25042981

Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.

Oliver T Burton1, Stephanie L Logsdon1, Joseph S Zhou1, Jaciel Medina-Tamayo1, Azza Abdel-Gadir1, Magali Noval Rivas1, Kyle J Koleoglou2, Talal A Chatila1, Lynda C Schneider1, Rima Rachid1, Dale T Umetsu1, Hans C Oettgen3.   

Abstract

BACKGROUND: Food-induced anaphylaxis is triggered by specific IgE antibodies. Paradoxically, some subjects with significant IgE levels can ingest allergenic foods without incident. Similarly, subjects completing oral immunotherapy (OIT) tolerate food challenges despite persistent high-titer food-specific IgE.
OBJECTIVE: We sought to test whether IgG antibodies induced by food immunotherapy prevent food-induced anaphylaxis and whether this occurs through the inhibitory receptor FcγRIIb.
METHODS: Food allergy-susceptible Il4raF709 mice were enterally sensitized to ovalbumin (OVA). Similarly sensitized IgE-deficient (IgE(-/-)) Il4raF709 mice, which can ingest OVA without anaphylaxis, were subjected to a high-dose enteral OVA desensitization protocol (OIT). Sera from both groups were tested for the ability to activate or inhibit bone marrow mast cells (BMMCs) exposed to allergen or to passively transfer allergy to naive hosts. In parallel experiments sera obtained from patients with peanut allergy before and after undergoing OIT were interrogated for their ability to enhance or suppress peanut-induced activation in an indirect assay by using basophils from nonallergic donors.
RESULTS: Il4raF709 mice exhibited strong OVA-specific IgE responses. Their sera efficiently sensitized BMMCs for activation by antigen challenge. Sera from Il4raF709/IgE(-/-) mice subjected to OVA OIT suppressed BMMC responses. This inhibition was IgG mediated and FcγRIIb dependent. Similarly, pre-OIT but not post-OIT sera from patients efficiently sensitized basophils for peanut-induced activation. IgG antibodies in post-OIT sera suppressed basophil activation by pre-OIT sera. This inhibition was blocked by antibodies against FcγRII.
CONCLUSION: Food-specific IgG antibodies, such as those induced during OIT, inhibit IgE-mediated reactions. Strategies that favor IgG responses might prove useful in the management of food allergy.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Food allergy; IgE; anaphylaxis; desensitization; oral immunotherapy; tolerance

Mesh:

Substances:

Year:  2014        PMID: 25042981      PMCID: PMC4261076          DOI: 10.1016/j.jaci.2014.05.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  40 in total

1.  A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils.

Authors:  S W Tam; S Demissie; D Thomas; M Daëron
Journal:  Allergy       Date:  2004-07       Impact factor: 13.146

2.  IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking.

Authors:  Richard T Strait; Suzanne C Morris; Fred D Finkelman
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

3.  Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.

Authors:  A Thyagarajan; S M Jones; A Calatroni; L Pons; M Kulis; C S Woo; M Kamalakannan; B P Vickery; A M Scurlock; A Wesley Burks; W G Shreffler
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

4.  A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody.

Authors:  L M Lichtenstein; N A Holtzman; L S Burnett
Journal:  J Immunol       Date:  1968-08       Impact factor: 5.422

5.  Basophil activation testing.

Authors:  Donald W MacGlashan
Journal:  J Allergy Clin Immunol       Date:  2013-08-16       Impact factor: 10.793

6.  A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy.

Authors:  Justin M Skripak; Scott D Nash; Hannah Rowley; Nga H Brereton; Susan Oh; Robert G Hamilton; Elizabeth C Matsui; A Wesley Burks; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2008-10-25       Impact factor: 10.793

7.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

8.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

9.  Immunologic changes associated with the development of tolerance in children with cow milk allergy.

Authors:  J M James; H A Sampson
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

10.  Differential regulation of mast cell degranulation versus cytokine secretion by the actin regulatory proteins Coronin1a and Coronin1b.

Authors:  Niko Föger; André Jenckel; Zane Orinska; Kyeong-Hee Lee; Andrew C Chan; Silvia Bulfone-Paus
Journal:  J Exp Med       Date:  2011-08-15       Impact factor: 14.307

View more
  70 in total

Review 1.  Evolution of Immune Responses in Food Immunotherapy.

Authors:  Johanna M Smeekens; Michael D Kulis
Journal:  Immunol Allergy Clin North Am       Date:  2019-11-06       Impact factor: 3.479

2.  Data-driven programmatic approach to analysis of basophil activation tests.

Authors:  Sarita U Patil; Agustin Calatroni; Michael Schneider; Johanna Steinbrecher; Neal Smith; Cecilia Washburn; Alex Ma; Wayne G Shreffler
Journal:  Cytometry B Clin Cytom       Date:  2017-07-05       Impact factor: 3.058

3.  Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies.

Authors:  Amanda J Stranks; Samantha C Minnicozzi; Samuel J Miller; Oliver T Burton; Stephanie L Logsdon; Jonathan M Spergel; Kari C Nadeau; Jacqueline A Pongracic; Dale T Umetsu; Rima Rachid; Andrew J MacGinnitie; Lynda C Schneider; Hans C Oettgen
Journal:  Ann Allergy Asthma Immunol       Date:  2018-11-04       Impact factor: 6.347

4.  Desensitization for Peanut Allergies in Children.

Authors:  Rekha D Jhamnani; Pamela Frischmeyer-Guerrerio
Journal:  Curr Treat Options Allergy       Date:  2016-07-21

Review 5.  Immunomodulatory effects of breast milk on food allergy.

Authors:  Kirsi M Järvinen; Hayley Martin; Michiko K Oyoshi
Journal:  Ann Allergy Asthma Immunol       Date:  2019-04-29       Impact factor: 6.347

Review 6.  How to Incorporate Oral Immunotherapy into Your Clinical Practice.

Authors:  Elissa M Abrams; Stephanie C Erdle; Scott B Cameron; Lianne Soller; Edmond S Chan
Journal:  Curr Allergy Asthma Rep       Date:  2021-04-30       Impact factor: 4.806

7.  Origins of peanut allergy-causing antibodies.

Authors:  Duane R Wesemann; Cathryn R Nagler
Journal:  Science       Date:  2020-03-06       Impact factor: 47.728

Review 8.  The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.

Authors:  Christina S K Yee; Rima Rachid
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

Review 9.  Recent developments in understanding the mechanisms of food allergy.

Authors:  Zoe C Schmiechen; Katherine A Weissler; Pamela A Frischmeyer-Guerrerio
Journal:  Curr Opin Pediatr       Date:  2019-12       Impact factor: 2.856

10.  Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.

Authors:  Sarita U Patil; Johanna Steinbrecher; Agustin Calatroni; Neal Smith; Alex Ma; Bert Ruiter; Yamini Virkud; Michael Schneider; Wayne G Shreffler
Journal:  J Allergy Clin Immunol       Date:  2019-08-01       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.